NCT04930640 is a NA clinical trial of SGF200 group in Immunity, sponsored by Chonbuk National University Hospital.

Who is sponsoring NCT04930640?

NCT04930640 is sponsored by Chonbuk National University Hospital.

What drugs are being tested in NCT04930640?

Interventions in NCT04930640: SGF200 group, Placebo.

Is NCT04930640 still recruiting?

NCT04930640 is currently completed. Last updated 18 June 2021.

Last reviewed 2021-06-18 · How we verify

NCT04930640

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of SGF200 on Immune Enhancement

Completed NA Last updated 18 June 2021

What this trial tests

NA trial testing SGF200 group in Immunity in 100 participants. Completed in 26 May 2021.

Timeline

25 January 2021

Primary endpoint
6 April 2021

26 May 2021

Quick facts

Lead sponsor	Chonbuk National University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	100
Start date	25 January 2021
Primary completion	6 April 2021
Estimated completion	26 May 2021
Sites	1 location across South Korea

Drugs / interventions tested

SGF200 group
Placebo

Conditions studied

Immunity — all drugs for Immunity →

Sponsor

Chonbuk National University Hospital

Who can join

50 and older, any sex, with Immunity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was conducted to investigate the efficacy and safety of SGF200 on immune enhancement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Immunity

Currently open trials in the same condition.

NCT07341750 — Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children · NA · recruiting
NCT06724185 — Effects of LP28 on Immunity Enhancement in the Elderly · NA · recruiting

Other Chonbuk National University Hospital trials

Trials by the same sponsor.

NCT05324800 — the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement · NA · unknown
NCT05450939 — Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture · unknown
NCT05190237 — the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement. · NA · completed
NCT05495191 — Signal Intensity Gradient in Cerebral Arteries · completed
NCT04940910 — The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04930640 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonbuk National University Hospital
Last refreshed: 18 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04930640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing